The lung is a vital mucosal organ that is constantly exposed to the external environment, and
as such, its defenses are continuously under threat. The pulmonary immune system has …

Objectives In some studies comparing triple with dual combination therapies in COPD there
might be a possible effect of inhaler bias resulting from different inhaler devices being used …

Chemotherapy-induced neuropathic pain is a debilitating and common side effect of cancer
treatment and so far no effective drug is available for treatment of the serious side effect …

Inhaled bronchodilators (alone or in combination) are the cornerstone of treatment for
symptomatic patients with COPD, either as initial/first-line treatment or for second …

Purpose Triple therapy to prevent exacerbations from chronic obstructive pulmonary disease
(COPD) is associated with improved health compared to single and dual-agent therapy in …

Chronic Obstructive Pulmonary Disease (COPD) is a chronic respiratory disease
characterized by a slow progression and caused by the inhalation of harmful particulate …

Chronic obstructive pulmonary disease (COPD) remains a leading cause of death
worldwide, yet only one new drug class has been approved in the last decade. However …

Purpose Chronic obstructive pulmonary disease (COPD) is characterized by high morbidity
and mortality, with a considerable consumption of healthcare resources (HRU). This study …

Chronic obstructive pulmonary disease (COPD) is associated with major healthcare and
socioeconomic burdens. International consortia recommend a personalized approach to …

Background The comparative efficacy of inhaled corticosteroid/long-acting muscarinic
antagonist/long-acting β 2-agonist (ICS/LAMA/LABA) triple therapy administered via single …